Repligen Corporation Overview
Pro stress-test →Repligen Corporation develops and commercializes bioprocessing technologies and systems for manufacturing biological drugs. The company serves biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research institutions globally, with a strategic focus on high-growth adjacent markets including cell and gene therapies.
Strategic Profile
Pro stress-test →Repligen is positioned as a core beneficiary of biopharma reshoring trends, with over 20% order growth and expanding Edge manufacturing footprint. The company targets attractive markets including monoclonal antibodies (8-10% market growth) and is moving into cell and gene therapies (over 30% market growth).
Competitive Landscape
Pro stress-test →Repligen competes in bioprocessing and life sciences tools, selling to biopharmaceutical companies, diagnostics firms, laboratory researchers, and contract manufacturing organizations. Primary competitors include other bioprocessing consumables suppliers such as Cytiva (part of Danaher), Sartorius, and Avantor.
Industry Context
Repligen Corporation operates in Life Sciences/Bioprocessing Technology.
Key facts
Founded: 1981 · Headquarters: Waltham, Massachusetts · Revenue: $~750M (2025 estimated) · Market cap: $7.9B